Christine Mateus

2003–2020 年に発表

別表記
Christine Matéus
41
論文数
30,593
被引用数
40
h 指数
41
i10 指数

被引用数

Christine Mateus の年別被引用数1995 年: 被引用 1 件1997 年: 被引用 1 件2000 年: 被引用 1 件2004 年: 被引用 5 件2005 年: 被引用 7 件2006 年: 被引用 2 件2007 年: 被引用 5 件2008 年: 被引用 7 件2009 年: 被引用 7 件2010 年: 被引用 17 件2011 年: 被引用 17 件2012 年: 被引用 42 件2013 年: 被引用 95 件2014 年: 被引用 186 件2015 年: 被引用 539 件2016 年: 被引用 888 件2017 年: 被引用 985 件2018 年: 被引用 924 件2019 年: 被引用 1,990 件2020 年: 被引用 2,203 件2021 年: 被引用 1,844 件2022 年: 被引用 1,308 件2023 年: 被引用 875 件2024 年: 被引用 1,131 件2025 年: 被引用 517 件2026 年: 被引用 9 件1996 年は被引用が無いため表示していません1998〜1999 年は被引用が無いため表示していません2001〜2003 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 4,590 件、この内訳の 27.4%中国: 引用元論文 2,447 件、この内訳の 14.6%フランス: 引用元論文 933 件、この内訳の 5.5%イタリア: 引用元論文 801 件、この内訳の 4.8%イギリス: 引用元論文 779 件、この内訳の 4.6%ドイツ: 引用元論文 775 件、この内訳の 4.6%日本: 引用元論文 633 件、この内訳の 3.8%オーストラリア: 引用元論文 616 件、この内訳の 3.7%カナダ: 引用元論文 502 件、この内訳の 3%オランダ: 引用元論文 483 件、この内訳の 2.9%スペイン: 引用元論文 416 件、この内訳の 2.5%スイス: 引用元論文 412 件、この内訳の 2.4%
0%27.4%その他 20.2%

分野

  • Medicine68.4%
  • Biochemistry, Genetics and Molecular Biology17.1%
  • Immunology and Microbiology10.5%
  • Engineering1.8%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • Neuroscience0.5%
  • その他1.2%

トピック

  • Cancer Immunotherapy and Biomarkers21.7%
  • Immunotherapy and Immune Responses8.9%
  • CAR-T cell therapy research7%
  • Immune Cell Function and Interaction4.8%
  • Immune cells in cancer2.6%
  • Melanoma and MAPK Pathways2.6%
  • その他52.4%

共著者

全論文

検索で開く
  1. PD-1 blockade induces responses by inhibiting adaptive immune resistance

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2014 被引用: 6,699

  2. Pembrolizumab versus Ipilimumab in Advanced Melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 被引用: 5,847

  3. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

    著者: , , , , , , , , , , , , , , , , , - Annals of Oncology 2017 被引用: 1,295

  4. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2020 被引用: 469

  5. Immune-related adverse events with immune checkpoint blockade: a comprehensive review

    著者: , , , , , , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2016 被引用: 2,129

  6. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

    著者: , , , , , , , , , , , , , , , , - Nature Reviews Clinical Oncology 2016 被引用: 1,100

  7. Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2013 被引用: 3,395

  8. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA 2016 被引用: 1,062

  9. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2014 被引用: 1,761

  10. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors

    著者: , , , , , , , , , , , , , - Journal of Hepatology 2018 被引用: 532

  11. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

    著者: , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2015 被引用: 893

  12. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease

    著者: , , , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2018 被引用: 311

  13. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab

    著者: , , , , , , , , , , , , , , , - JAMA Dermatology 2015 被引用: 650

  14. Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

    著者: , , , , , , , , , , , , , , , , , , - Journal of Crohn s and Colitis 2016 被引用: 342

  15. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anne-Laure Voisin, Bertrand Godeau, Christophe Massard, Vincent Ribrag, Aurélien Marabelle, Marc Michel, Olivier Lambotte - The Lancet Haematology 2018 被引用: 292

  16. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sophie Gad, Stéphane Richard, Jérôme Couturier, Bin Tean Teh, Paola Ghiorzo, Lorenza Pastorino, Susana Puig, Célia Bádenas, Håkan Olsson, Christian Ingvar, Etienne Rouleau, Rosette Lidereau, Philippe Bahadoran, Philippe Vielh, Eve Corda, Hélène Blanché, Diana Zélénika, Pilar Galán, The French Familial Melanoma Study Group, F. Aubin, Bertrand Bachollet, Céline Becuwe, Pascaline Berthet, Yves Jean Bignon, Valérie Bonadona, Jean‐Louis Bonafé, Marie‐Noëlle Bonnet‐Dupeyron, F. Cambazard, J. Chevrant‐Breton, Isabelle Coupier, S. Dalac, Liliane Demange, M. D’Incan, Catherine Dugast, Laurence Faivre, Lynda Vincent-Fétita, Marion Gauthier-Villars, Brigitte Gilbert, Florent Grange, Jean‐Jacques Grob, Philippe Humbert, Nicolas Janin, Pascal Joly, Delphine Kérob, Christine Lasset, Dominique Leroux, J. Levang, Jean‐Marc Limacher, C. Bulaï Livideanu, Michel Longy, Alain Lortholary, Dominique Stoppa-Lyonnet, Sandrine Mansard, L Mansuy, Karine Marrou, Christine Matéus, Christine Maugard, Nicolás Meyer, Catherine Noguès, P Souteyrand, Laurence Venat‐Bouvet, Hélène Zattara, Valérie Chaudru, Gilbert Lenoir, Mark Lathrop, Irwin Davidson, Marie-Françoise Avril, Florence Démenais, Robert Ballotti, Brigitte Bressac–de Paillerets - Nature 2011 被引用: 522

  17. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis

    著者: , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2017 被引用: 199

  18. An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells

    著者: , , , , , , , , , , , , , , , , - Nature Communications 2019 被引用: 100

  19. The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Roger von Moos, Patrik Weder, Tabea Wilhelm, Daniela Göppner, Reinhard Dummer, Lucie Heinzerling - PLoS ONE 2013 被引用: 470

  20. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies

    著者: , , , , , , , , , , , , , , , , , , - Annals of Oncology 2017 被引用: 154

  21. The 2016–2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Aurélien Marabelle, Stéphane Champiat, Olivier Lambotte - European Journal of Cancer 2020 被引用: 59

  22. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Laurence Zitvogel - Cell Research 2015 被引用: 160

  23. Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy

    著者: , , , , , , , , , , , , - American Journal of Ophthalmology 2019 被引用: 88

  24. Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Crohn s and Colitis 2017 被引用: 166